KOSDAQ - Delayed Quote KRW
Korea Arlico Pharm Co.,Ltd. (260660.KQ)
4,395.00
-70.00
(-1.57%)
At close: 3:30:30 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hang-Gu Lee | Chief Executive Officer | -- | -- | 1961 |
Korea Arlico Pharm Co.,Ltd.
Alico Pharmaceutical Building
7-21 Baumoe-ro 27- gil Seocho-gu
Seoul
South Korea
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.
Corporate Governance
Korea Arlico Pharm Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
December 27, 2024 at 12:00 AM UTC
Ex-Dividend Date